CONSTANT LEVERAGE SHORT - UCB Share Price

A0EOB

FRBNPP06MX11

Market Closed - Euronext Paris 17:30:01 19/06/2024 BST
1.592 ^EUR	-0.44%

Current month	-34.40%
1 month	-43.63%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : Financial Reporting Document	06-15	PU
UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels	06-13	CI
UCB : Financial Reporting Document	06-13	PU
UCB to Share First Presentations of BIMZELX®? (bimekizumab-bkzx) Two-Year Data in Axial Spondyloarthritis and Psoriatic Arthritis at EULAR 2024	06-12	CI

More news

Quotes 5-day view

Date	Price	Change
19/06/24	1.592	-0.44%
18/06/24	1.599	-5.05%
17/06/24	1.684	+1.57%
14/06/24	1.658	-7.27%
13/06/24	1.788	-2.13%

Real-time Euronext Paris

Last update June 19, 2024 at 05:30 pm

More quotes

Static data

Product type	Exotic Products
Buy / Sell	PUT
Underlying	UCB
Issuer	BNP Paribas
	A0EOB
ISIN	FRBNPP06MX11
Date issued	27/03/2024
Maturity	Unlimited
Parity	1 : 1
Emission price	5 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	5.41 €
Lowest since issue	1.565 €
Spread	0.083 €
Spread %	5.08%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

139 EUR

Average target price

135.5 EUR

Spread / Average Target

-2.56%

Consensus